20:41 , Jan 18, 2019 |  BC Week In Review  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
23:21 , Jan 17, 2019 |  BC Extra  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
15:59 , Nov 16, 2018 |  BC Week In Review  |  Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) in a Nov. 15 deal that highlights how far Arena’s come since it shifted its focus...
00:26 , Nov 16, 2018 |  BC Extra  |  Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) on Thursday in a deal that highlights how far Arena’s come since it shifted its focus...
20:32 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Arena's olorinab improves abdominal pain in Crohn's patients in Phase IIa

Arena Pharmaceuticals Inc. (NASDSAQ:ARNA) said olorinab (APD371) significantly improved average abdominal pain score from baseline to weeks four and eight in a Phase IIa trial to treat abdominal pain in patients with Crohn’s disease. The...
03:13 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

Eisai's Belviq does not increase MACE in CVOT for weight management drug

Eisai Co. Ltd. (Tokyo:4523) said Belviq lorcaserin met the primary safety endpoint by not increasing the incidence of major adverse cardiovascular events (MACE), comprising CV death, non-fatal myocardial infarction (MI) and non-fatal stroke, in the...
17:45 , Aug 3, 2018 |  BC Week In Review  |  Company News

Eisai grants CY Biotech Greater China rights to lorcaserin

Eisai Co. Ltd. (Tokyo:4523) granted exclusive rights to CY Biotech Co. Ltd. (Taipei, Taiwan) to develop and market obesity drug lorcaserin (APD356) in Greater China, including Hong Kong and Macao. Under the deal, Eisai will...
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
23:28 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Addiction Rat studies identified a carboxamide-based 5-HT2C receptor positive allosteric modulator (PAM) that could help treat cocaine addiction. Chemical synthesis and in vitro activity testing of analogs of the 5-HT2C receptor PAM lincomycin yielded...